An advisory panel for the Centers for Disease Control and Prevention on Friday recommended that the U.S. resume use of the Johnson & Johnson coronavirus vaccine, saying the benefits outweighed the risk of a rare blood clot disorder.
Why it matters: The recommendation likely paves the way for the U.S. to lift its pause on the one-shot vaccine. The Biden administration has said it will take the panel's recommendations into account as it makes a determination on the vaccine's use.
- The panel's vote on Friday was 10-4 in favor of recommending the use of the J&J vaccine for "persons 18 years of age and older in the U.S. population under the FDA's Emergency Use Authorization." One voting member abstained.
Background: The Food and Drug Administration on April 13 recommended an immediate halt to the use of the J&J vaccine, citing cases of a rare blood clot disorder that six women developed within two weeks of receiving the shot.
- All 50 states, Washington, D.C., and Puerto Rico paused or recommended a halt on the use of that vaccine.
- The CDC said Friday at least nine additional women have developed blood clots, but said the chances of people developing the condition remains extremely low.
What to watch: The FDA is expected to soon make its decision on Johnson & Johnson's vaccine.